GSK To Pay States, DC $41M Over Drugmaking Lapses
GlaxoSmithKline LLC and a related company will pay $40.75 million to the District of Columbia and 37 states, including Oregon and Illinois, to resolve allegations of substandard manufacturing processes at one...To view the full article, register now.
Already a subscriber? Click here to view full article